Northside Hospital, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.northside.com
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
Completed
- Conditions
- AnxietyDistressDepressionFatigue
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01084694
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2
Terminated
- Conditions
- Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00827099
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2
Terminated
- Conditions
- Myelodysplastic SyndromesLymphomaLeukemiaMyelodysplastic/Myeloproliferative Diseases
- Interventions
- Biological: alemtuzumabBiological: graft-versus-tumor induction therapyBiological: rituximabProcedure: allogeneic bone marrow transplantation
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00818961
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2
Completed
- Conditions
- Myeloproliferative DisordersKidney CancerLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Interventions
- Biological: anti-thymocyte globulinProcedure: nonmyeloablative allogeneic HSCT
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00787761
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Phase 2
Completed
- Conditions
- LymphomaLeukemiaMyelodysplastic Syndromes
- Interventions
- Procedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00782379
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath